Suchergebnisse - (Person:"Wei, Xiang")

PubPharm (8)

1

Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer : a systematic review and meta-analysis

enthalten in: Lung | 2012

von Qi, W. | Tang, L. | He, A. | +3

CommentIn: Lung. 2012 Dec;190(6):591-2; author reply 592. - PMID 23081731

2

Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

enthalten in: Lung | 2012

von Qi, W. | Tang, L. | He, A. | +3

3

Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

enthalten in: Lung | 2012

von Qi, W. | Tang, L. | He, A. | +3

4

Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

enthalten in: Lung | 2012

von Qi, W. | Tang, L. | He, A. | +3

5

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer : a meta-analysis of four randomized controlled trials

enthalten in: Lung | 2011

von Qi, W. | Tang, L. | He, A. | +2

6

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

enthalten in: Lung | 2011

von Qi, W. | Tang, L. | He, A. | +2

7

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

enthalten in: Lung | 2011

von Qi, W. | Tang, L. | He, A. | +2

8

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

enthalten in: Lung | 2011

von Qi, W. | Tang, L. | He, A. | +2

1
[1]